A new dawn for gemtuzumab ozogamicin?
A partir d'une revue de la littérature publiée avant mai 2013 (5 essais randomisés identifiés, 3 325 patients au total), cette méta-analyse évalue l'efficacité de l'ajout du gemtuzumab ozogamicine à une chimiothérapie d'induction chez les patients adultes atteints d'une leucémie myéloïde aiguë
In The Lancet Oncology , Robert Hills and colleagues describe results of a meta-analysis of individual patient data from five randomised controlled trials to assess the addition of gemtuzumab ozogamicin to induction chemotherapy in adults with newly diagnosed acute myeloid leukaemia.
Gemtuzumab ozogamicin was withdrawn from the US market in June, 2010, after the disappointing results of the Southwest Oncology Group (SWOG) S0106 study, which was done to justify the original accelerated approval of ...
The Lancet Oncology , commentaire, 2013